Paul McCormac - 02 Nov 2023 Form 3 Insider Report for Lexeo Therapeutics, Inc. (LXEO)

Role
Chief Technical Officer
Signature
/s/ Jenny Robertson, Attorney-in-Fact
Issuer symbol
LXEO
Transactions as of
02 Nov 2023
Net transactions value
$0
Form type
3
Filing time
02 Nov 2023, 21:38:37 UTC
Next filing
09 Nov 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding LXEO Common Stock 14,158 02 Nov 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding LXEO Series B convertible preferred stock 02 Nov 2023 Common Stock 2,743 Direct F1
holding LXEO Employee Stock Option (right to buy) 02 Nov 2023 Common Stock 46,001 $2.33 Direct F2
holding LXEO Employee Stock Option (right to buy) 02 Nov 2023 Common Stock 112,028 $4.87 Direct F3
holding LXEO Employee Stock Option (right to buy) 02 Nov 2023 Common Stock 9,438 $11.02 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series B convertible preferred stock is convertible into Common Stock on a 1-for-10.594230 at any time at the Reporting Person's election, and automatically upon the closing of the Issuer's initial public offering without payment or further consideration. Excludes shares of Common Stock issuable upon the closing of the Issuer's initial public offering pursuant to anti-dilution adjustment provisions of the Series B convertible preferred stock. The shares have no expiration date.
F2 25% of the shares underlying the option vested on March 22, 2022, and 1/48th of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
F3 25% of the shares underlying the option vested on August 11, 2022, and 1/48th of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
F4 25% of the shares underlying the option shall vest on August 22, 2024, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney